DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

Vision – Improve the health and lives of people with Parkinson’s disease through innovative, clinically meaningful treatments

Parkinson's Program Cover Image
»  Click Image to View Program Booklet

Parkinson's Research Program Overview Image
» Click Image to View Program Overview

Parkinson’s disease (PD) is a degenerative movement disorder of the central nervous system resulting from a loss of neurons in a region of the brain called the substantia nigra. These neurons produce dopamine, a neurotransmitter important for motor control; however, as PD progresses, the death of dopaminergic neurons results in reduced dopamine levels and impairment of motor control.

For FY22, Congress transitioned the Neurotoxin Exposure Treatment Parkinson’s (NETP) program to the Parkinson’s Research Program (PRP) and broadened the research from neurotoxin exposure treatment PD research to all types of PD research. The PRP challenges the scientific community to develop the most impactful research that will advance the understanding of the disease, with the ultimate goal of ending PD.

For information on toxic exposure research, please go to the Toxic Exposures Research Program at CDMRP.



Congressional Appropriations

Congressional Appropriations

  • $16 million
    FY22
  • $16 million
    FY23

Funding Summary

Funding
Summary















...

Peer Review Participants


Related Videos

Dr. Angus Nairn Video

Yale University School of Medicine
Proteomic Methods for Analyzing Protein in Dopaminergic Neurons

Dr. Andrew Singleton Video

National Institute on Aging
Whole-Genome Sequencing
in Parkinson’s Disease

Dr. Kenneth Marek Video

Institute for Neurodegenerative Disorders
Evaluating the Natural History of Prodromal PD in the PARS Cohort

Dr. Caroline Tanner

University of California, San Francisco
Persistent Organic Pollutants and Parkinson’s disease in Native Populations of Hawaii and Alaska

Dr. Paul Greengard

Rockefeller University
New P11 Biomarker Predicts Clinical Effectiveness of Antidepressant Drugs

Dr. Howard J. Federoff

University of California, Irvine
PGC-1α Therapy for
Parkinson Neurodegeneration

news_icon News & Highlights

Vision

Improve the health and lives of people with Parkinson’s disease through innovative, clinically meaningful treatments

Mission

To support high impact Parkinson’s research that alters disease progression, improves disease symptoms, and develops treatments that benefit Service Members, Veterans, and all others living with Parkinson’s disease







Last updated Sunday, December 31, 1600